The advantages of ‘biosimilar’ drugs

The rise of ‘generic’ biologics should mean cost savings for employer drug plans
By Bill Zolis
|Canadian HR Reporter|Last Updated: 02/21/2017

Most of us are familiar with the difference between brand-name drugs and their generic equivalents. Basically, the generics are “bio-equivalent” to the brand names and are, for all practical purposes, the same — only cheaper. 

Now there’s a new term, and a whole new area of prescribing options, that we will be hearing a lot more about in the coming months and years: Biosimilars.

Biosimilars can’t strictly be described as “generic” versions of biologic drugs although, like the generics, they do provide less expensive options to patented brand-name biologics.